Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus.
To evaluate empirical therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, a randomized, prospective, open-label investigation was performed. The overall clinical failure rate was 9%, with all failures occurring in the trimethoprim-sulfamethoxazole group. However, there was no significant difference between the clinical failure rate of empirical trimethoprim-sulfamethoxazole therapy and that of doxycycline therapy.
Cenizal
Mary Jo
MJ
University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, USA.
Skiest
Daniel
D
Luber
Samuel
S
Bedimo
Roger
R
Davis
Pat
P
Fox
Patrick
P
Delaney
Kathleen
K
Hardy
R Doug
RD
D000293:Adolescent; D000328:Adult; D000368:Aged; D002481:Cellulitis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D036262:Empirical Research; D005500:Follow-Up Studies; D006801:Humans; D016106:Methicillin Resistance / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010045:Outpatients; D015995:Prevalence; D011446:Prospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000145:classification* / Q000187:drug effects / Q000235:genetics; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014295:Trimethoprim / Q000627:therapeutic use
D014295:Trimethoprim; D013420:Sulfamethoxazole; D004318:Doxycycline